Abstract Body

Background:

The CDC estimates 57% of US persons with HIV (PWH) achieve viral suppression. Early initiation of ART is recommended, but objective baseline tests with predictive ability to distinguish persons at risk of poor ART adherence and engagement in care are lacking. We evaluated the utility of baseline urine toxicology testing for methamphetamine (UTOXM) use in PWH starting oral ART in our West Coast US setting to predict adherence and characteristics associated with poor engagement in care.

Methods:

PWH initiating ART with ingestible-sensor-enabled antiretroviral technology (IS-ARVs) to observe medication taking for the first 16 weeks of treatment had a baseline UTOXM, with demographics and self-report questionnaires obtained. UTOXM ability to predict IS-ARV-confirmed doses (taking & timing); persistence on study; and baseline demographics and questionnaires were analyzed using mixed-effects logistic regression; Kaplan-Meier curves; and linear models, respectively. No causal analyses were attempted.

Results:

Sixty-three enrolled participants prescribed IS-ARVs had median age 37 (IQR 30-46) yrs, 82.5% were male, 33.3% White, 34.9% Hispanic, 22.2% African American, 3.2% Asian. UTOXM was negative in 42, positive in 21. Over 6049 observation days evaluated in longitudinal mixed effects logistic regression revealed a negative baseline UTOXM (compared to those who tested positive) was associated with a daily confirmed dose odds ratio (OR) of 3.12 (CI 1.71-5.71), P<0.001 and a regularity of dose timing OR of 5.05 (CL 2.43-10.6), P<0.001. A baseline positive UTOXM (vs negative) was associated with: higher homelessness/transient housing rate (52.4% vs 21.4% P=0.028); lower mean income $7,400 vs $31,500, P=0.042; more depression as measured by Mood PHQ8 11.8 vs 6.9, P=0.001 and higher Life Chaos score 14.2 vs 9.0, P=0.001. UTOXM positive 16-week persistence on study was 0.333 (0.182-0.610) vs negative 0.619 (95% CI 0.488-0.785), P=0.0098.

Conclusions:

Baseline positive UTOXM in PWH starting oral ART predicted highly significant differences in treatment adherence & persistence on study (a surrogate for care retention); and identified a distinct subpopulation in our West Coast US setting with multiple attributes, including life chaos & depression, associated with poor care engagement. Baseline UTOX may be a useful, simple screening tool to identify PWH requiring differentiated care and adherence support on initiation of oral ART, and may be easily employed in mobile testing sites offering quick start care.